{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:02:57Z","timestamp":1791471777493,"version":"4.3.4"},"reference-count":20,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Abrocitinib treatment previously showed clinically meaningful improvements in skin signs and symptoms in patients with moderate\u2010to\u2010severe atopic dermatitis (AD) up to 48\u2009weeks, with a manageable safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To further evaluate long\u2010term efficacy and patient\u2010reported outcomes (PROs) with abrocitinib in patients with moderate\u2010to\u2010severe AD up to 112\u2009weeks of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>JADE EXTEND (NCT03422822), an ongoing, phase 3, long\u2010term extension study of previous abrocitinib trials, includes patients from qualifying trials MOA (NCT03915496), MONO\u20101 (NCT03349060), MONO\u20102 (NCT03575871), COMPARE (NCT03720470), TEEN (NCT03796676) and DARE (NCT04345367). Efficacy assessments include the proportion of patients achieving IGA score of 0 or 1 (IGA 0\/1); absolute Eczema Area and Severity Index \u22647 (EASI\u2009\u2264\u20097), \u226575%\/\u226590%\/100% improvement in EASI (EASI\u201075\/\u201090\/\u2010100); \u22654\u2010point improvement in Peak Pruritus Numerical Rating Scale (PP\u2010NRS4); PP\u2010NRS score of 0 or 1 (PP\u2010NRS 0\/1); EASI\u201090\u2009+\u2009PP\u2010NRS 0\/1. PROs include Dermatology Life Quality Index score of 0 or 1 (DLQI 0\/1), Children's Dermatology Life Quality Index score of 0 or 1 (CDLQI 0\/1), Patient Global Assessment score of 0 or 1 (PtGA 0\/1), and \u22654\u2010point improvement in Patient\u2010Oriented Eczema Measure (POEM\u2009\u2265\u20094). Data cut\u2010off: 5 September 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At data cut\u2010off, 403 (42%) and 425 (56%) patients received abrocitinib 200\u2009mg and abrocitinib 100\u2009mg, respectively, for \u2265112\u2009weeks. Week 112 efficacy responses were IGA 0\/1 57% and 52%; EASI \u22647 81% and 77%; EASI\u201075 84% and 78%; EASI\u201090 61% and 54%; EASI\u2010100 26% and 21%; PP\u2010NRS4 70% and 58%; PP\u2010NRS 0\/1 43% and 33%; EASI\u201090\u2009+\u2009PP\u2010NRS 0\/1 37% and 30%. Week 112 PROs were DLQI 0\/1 43% and 41%; CDLQI 0\/1 59% and 39%; PtGA 0\/1 75% and 72%; POEM \u22654 88% and 81%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Abrocitinib treatment resulted in clinically meaningful outcomes and improvements in PROs, including high\u2010threshold endpoints, in substantial proportions of patients with moderate\u2010to\u2010severe AD up to 2\u2009years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.70439","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:12:08Z","timestamp":1777378328000},"page":"1372-1381","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long\u2010term efficacy of abrocitinib in patients with moderate\u2010to\u2010severe atopic dermatitis to 2\u2009years"],"prefix":"10.1111","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-0113","authenticated-orcid":false,"given":"Melinda J.","family":"Gooderham","sequence":"first","affiliation":[{"name":"SKiN Centre for Dermatology  Peterborough Ontario Canada"},{"name":"Queen's University  Kingston Ontario Canada"},{"name":"Probity Medical Research  Waterloo Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"The George Washington University School of Medicine and Health Sciences  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"De Bruin\u2010Weller","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Kircik","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai  New York New York USA"},{"name":"Indiana University School of Medicine  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"University of L\u00fcbeck  L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuotao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Tianjin Institute of Integrative Dermatology, Tianjin Academy of Traditional Chinese Medicine, Affiliated Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1032-9347","authenticated-orcid":false,"given":"Fernando","family":"Valenzuela","sequence":"additional","affiliation":[{"name":"University of Chile and Probity Medical Research  Santiago Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Nomura","sequence":"additional","affiliation":[{"name":"Institute of Medicine University of Tsukuba  Tsukuba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Selfridge","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Fan","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Myers","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Biswas","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleem A.","family":"Farooqui","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D UK Ltd, Sandwich  Kent UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8547-6624","authenticated-orcid":false,"given":"Melissa","family":"Watkins","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herwig","family":"Koppensteiner","sequence":"additional","affiliation":[{"name":"Pfizer Corporation Austria GmbH  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02519-4"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.10.043"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.1572"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.07.012"},{"key":"e_1_2_14_7_1","unstructured":"European Medicines Agency.CIBINQO\u00ae (abrocitinib). Summary of product characteristics. Pfizer Europe MA EEIG. Belgium 2021. [cited 2025 April 14]. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/cibinqo\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_14_8_1","unstructured":"Pfizer Inc.Japan's MHLW approves Pfizer's CIBINQO\u00ae (abrocitinib) for adults and adolescents with moderate to severe atopic dermatitis. Pfizer Inc. New York NY 2021. [cited 2025 April 14]. Available from:https:\/\/www.pfizer.com\/news\/press\u2010release\/press\u2010release\u2010detail\/japans\u2010mhlw\u2010approves\u2010pfizers\u2010cibinqor\u2010abrocitinib\u2010adults."},{"key":"e_1_2_14_9_1","unstructured":"Pfizer Inc.CIBINQO (abrocitinib) tablets for oral use. Prescribing information. Pfizer Inc.; New York NY 2022. [cited 2025 April 14]. Available from:https:\/\/cdn.pfizer.com\/pfizercom\/USPI_Med_Guide_CIBINQO_Abrocitinib_tablet.pdf."},{"key":"e_1_2_14_10_1","unstructured":"Pfizer Limited.CIBINQO 100 mg film\u2010coated tablets. Summary of product characteristics. Pfizer Limited. Kent UK 2021. [cited 2025 April 14]. Available from:https:\/\/www.medicines.org.uk\/emc\/product\/12873\/smpc."},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01199-0"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019380"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2830"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19280"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19254"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00869-w"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.16512"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20229"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000346247"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70439","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70439","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:59:18Z","timestamp":1785499158000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/jdv.70439"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70439","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"2025-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}